Theraclion names Vincent Gardès board chairman, replacing Claude Lenoir

  • Theraclion appointed Vincent Gardès as chairman of its board with immediate effect, replacing interim chairman Claude Lenoir, who remains a director.
  • Gardès joined the board on June 18, 2026, following a period as an observer.
  • He is a MedTech executive with 30 years’ experience; he led Vexim through its sale to Stryker.
  • He later ran Germitec’s European buildout and US market entry, most recently leading Amber Implants through commercialization.
  • The change comes as Sonovein gains traction in Europe, expands into China, and advances its US market-access and FDA filing steps.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theraclion SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260708013470) on July 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.